Oral Cancer News and Research

RSS

Oral cancer is the sixth most common type of cancer worldwide and in the U.S., one person dies every hour from the disease. According to American Cancer Society data, nearly as many women will be diagnosed with oral cancer as with cervical cancer this year. The key to reducing the impact of this disease is early detection.

Scientists identify potential marker for recurring HPV-positive oropharyngeal cancer

A look-back analysis of HPV infection antibodies in patients treated for oropharyngeal (mouth and throat) cancers linked to HPV infection suggests at least one of the antibodies could be useful in identifying those at risk for a recurrence of the cancer, say scientists at The Johns Hopkins University.

7 Feb 2016

Researchers partner to help personalize cancer care

Researchers at the University of Iowa College of Dentistry are partnering with a private company to develop computer simulations that can help personalize cancer care by predicting how a patient will respond to a drug treatment.

7 Dec 2015

New tool could help identify patients most likely to benefit from chemoprevention

A team of scientists, led by researchers at University of California, San Diego Moores Cancer Center and The University of Texas MD Anderson Cancer Center, report that a genetic biomarker called loss of heterozygosity or LOH is able to predict which patients with premalignant mouth lesions are at highest risk of developing oral cancer.

6 Nov 2015

Research sheds new light on the fight against tonsil cancer

Researchers at Simon Fraser University and the BC Cancer Agency have developed a groundbreaking method to identify and separate stem cells that reside in the tonsils. Their research, which sheds new light on the fight against oral cancer, is published today in the journal Stem Cell Reports.

3 Nov 2015

UF Health researcher reveals how betel nut's psychoactive chemical works in the brain

For hundreds of millions of people around the world, chewing betel nut produces a cheap, quick high but also raises the risk of addiction and oral cancer. Now, new findings by a University of Florida Health researcher reveal how the nut's psychoactive chemical works in the brain and suggest that an addiction treatment may already exist.

22 Oct 2015

Study: High school athletes use smokeless tobacco at a higher rate compared to non-athletes

High school athletes who play on sports teams smoke tobacco products at a lower rate than non-athletes, but use smokeless tobacco at a higher rate, according to a study published by the Centers for Disease Control and Prevention in today's Morbidity and Mortality Weekly Report (MMWR).

3 Sep 2015

Researcher reveals link between inflammatory response of neutrophils and spread of oral cancer

An abnormal immune response or "feedback loop" could very well be the underlying cause of metastases in oral cancers, according to Dr. Marco Magalhaes, Assistant Professor at the University of Toronto's Faculty of Dentistry and lead researcher in a study published in the journal Cancer Immunology Research.

7 Aug 2015

Patients with HPV traces post-treatment more likely to have oropharyngeal cancer recurrence

Oropharyngeal cancer patients who were found to have detectable traces of human papillomavirus type 16 (HPV16) in their saliva following cancer treatment are at an increased risk for recurrence, a study led by researchers at the Johns Hopkins Bloomberg School of Public Health has found.

31 Jul 2015

Taiho, Servier sign exclusive license agreement to develop and commercialize TAS-102 drug

Taiho Pharmaceutical Co., Ltd.(Japan) and Servier (France) announced on June 15 that they have entered into an exclusive license agreement on June 12, 2015 for the development and commercialization of TAS-102 (nonproprietary names: trifluridine and tipiracil hydrochloride) in Europe and other countries.

15 Jun 2015

Combination of cobimetinib and vemurafenib can halt progression of metastatic melanoma for one year

Data from the pivotal coBRIM Phase III study, presented by Lead Investigator Dr James Larkin today at the American Society of Clinical Oncology (ASCO) annual meeting, demonstrate that Roche’s investigational MEK inhibitor cobimetinib, used in combination with BRAF inhibitor vemurafenib, typically offers people with previously untreated advanced metastatic melanoma (BRAFV600 mutation-positive unresectable or metastatic) one full year (median 12.3 months) without their disease worsening.

2 Jun 2015

Penn researchers to present clinical data at 2015 ASCO Annual Meeting

Researchers from the Abramson Cancer Center of the University of Pennsylvania and Penn's Perelman School of Medicine will present results from several clinical trials and other key studies during the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting from May 29 through June 2.

30 May 2015

OSU researchers find promising approach to treating epithelial cancer

Researchers at Oregon State University are pursuing a new concept in treatment of epithelial cancer, especially head and neck cancer, by using two promising "analogs" of an old compound that was once studied as a potent anti-tumor agent, but long ago abandoned because it was too toxic.

19 May 2015

Oral, Head & Neck Cancer Awareness Week: Mount Sinai experts to share tips on cancer prevention

Mouth and throat cancers are the fastest rising cancers today. They account for over 40,000 cases per year in the U.S. The American Cancer Society estimates that there will be 121,790 new cases of head and neck cancer diagnosed in 2015 and 14,240 deaths. These numbers include tongue cancer, throat cancers caused by the human papillomavirus or HPV, voice box cancer, melanoma of the face and thyroid cancers.

8 Apr 2015

Dental experts join Oral Cancer Foundation to raise awareness about oral cancer

When oral and oropharyngeal cancers (cancers of the mouth and upper throat) are detected and treated early in their development, survival rates can improve significantly. Regular oral cancer examinations performed by your oral health professional remain the best method for detecting oral cancer in its early stages.

3 Apr 2015

Study: Green tea compound may activate a cycle that kills oral cancer cells

A compound found in green tea may trigger a cycle that kills oral cancer cells while leaving healthy cells alone, according to Penn State food scientists. The research could lead to treatments for oral cancer, as well as other types of cancer.

28 Jan 2015

TOSH Program aims to improve oral-systemic health

Improving oral health is a leading population health goal; however, curricula preparing health professionals have a dearth of oral health content and clinical experiences. Funded by a grant from the Health Resources and Service Administration, New York University College of Nursing's Teaching Oral-Systemic Health Program is working to build interprofessional oral health workforce capacity which addresses a significant public health issue, increases oral health care access, and improves oral-systemic health across the lifespan.

23 Jan 2015

DiaCarta raises $8 million in Series A financing from BVCF

DiaCarta, Inc., a privately-held biotechnology company raised $8 million in Series A financing from BVCF (BioVeda China Fund). Proceeds from Series A financing will be used to expand the product portfolio and support global commercialization. Dr. Weixin Xu of BVCF will join DiaCarta board of directors.

9 Jan 2015

Olaparib shows promise for advanced cancers associated with BRCA1 and BRCA2 mutations

Olaparib, an experimental twice-daily oral cancer drug, produces an overall tumor response rate of 26 percent in several advanced cancers associated with BRCA1 and BRCA2 mutations, according to new research co-led by the Abramson Cancer Center of the University of Pennsylvania.

7 Nov 2014

UCLA research could lead to simple saliva test for early diagnosis of deadly diseases

UCLA research could lead to a simple saliva test capable of diagnosing — at an early stage — diabetes and cancer, and perhaps neurological disorders and autoimmune diseases.

30 Oct 2014

Generic aromatase inhibitors increase breast cancer treatment adherence by 50%

Although oral hormonal therapy is known to substantially reduce breast cancer recurrence in women with hormone receptor-positive tumors, about one-half of patients fail to take their medications as directed. A new study by Columbia University Medical Center researchers has found that the introduction of generic aromatase inhibitors (the most common type of hormone therapy), which are considerably less expensive than their brand name counterparts, increased treatment adherence by 50 percent.

28 Oct 2014